- Home
- PXLW vs BTAI Comparison
PXLW vs BTAI Comparison
Compare PXLW & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- BTAI
- Stock Information
- Founded
- PXLW 1997
- BTAI 2017
- Country
- PXLW United States
- BTAI United States
- Employees
- PXLW N/A
- BTAI N/A
- Industry
- PXLW Semiconductors
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- PXLW Technology
- BTAI Health Care
- Exchange
- PXLW Nasdaq
- BTAI Nasdaq
- Market Cap
- PXLW 42.0M
- BTAI 48.3M
- IPO Year
- PXLW 2000
- BTAI 2018
- Fundamental
- Price
- PXLW $6.13
- BTAI $1.77
- Analyst Decision
- PXLW Strong Buy
- BTAI Buy
- Analyst Count
- PXLW 3
- BTAI 5
- Target Price
- PXLW $13.67
- BTAI $32.80
- AVG Volume (30 Days)
- PXLW 465.8K
- BTAI 819.3K
- Earning Date
- PXLW 11-11-2025
- BTAI 11-12-2025
- Dividend Yield
- PXLW N/A
- BTAI N/A
- EPS Growth
- PXLW N/A
- BTAI N/A
- EPS
- PXLW N/A
- BTAI N/A
- Revenue
- PXLW $33,961,000.00
- BTAI $868,000.00
- Revenue This Year
- PXLW N/A
- BTAI N/A
- Revenue Next Year
- PXLW $23.74
- BTAI $544.99
- P/E Ratio
- PXLW N/A
- BTAI N/A
- Revenue Growth
- PXLW N/A
- BTAI N/A
- 52 Week Low
- PXLW $4.67
- BTAI $1.17
- 52 Week High
- PXLW $15.42
- BTAI $12.16
- Technical
- Relative Strength Index (RSI)
- PXLW 36.39
- BTAI 28.80
- Support Level
- PXLW $6.00
- BTAI $2.14
- Resistance Level
- PXLW $6.47
- BTAI $2.46
- Average True Range (ATR)
- PXLW 0.40
- BTAI 0.13
- MACD
- PXLW -0.12
- BTAI -0.02
- Stochastic Oscillator
- PXLW 9.68
- BTAI 5.15
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.